Vasoactive intestinal peptide represses activation of tumor-associated macrophages in gastric cancer via regulation of TNFα, IL-6, IL-12 and iNOS

Chen,Lu; Yuan,Weijie; Chen,Zhikang; Wu,Shaobin; Ge,Jie; Chen,Jinxiang; Chen,Zihua

doi:10.3892/ijo.2015.3126

Vasoactive intestinal peptide represses activation of tumor-associated macrophages in gastric cancer via regulation of TNFα, IL-6, IL-12 and iNOS

Authors:
- Lu Chen
- Weijie Yuan
- Zhikang Chen
- Shaobin Wu
- Jie Ge
- Jinxiang Chen
- Zihua Chen
View Affiliations

Affiliations: Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, P.R. China
Published online on: August 19, 2015 https://doi.org/10.3892/ijo.2015.3126
Pages: 1361-1370

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vasoactive intestinal peptide (VIP) has been regarded as deactivator for macrophages. However, the depressive effect of VIP on tumor-associated macrophages (TAM) has not been recognized. In the present study, we investigated the effect of VIP on gastric cancer via TAM by suppressing expression levels of TNFα, IL-6, IL-12 and iNOS. Real-time PCR was carried out to examine the expression of CD68 to determine the levels of TAM. The effect of VIP on cell activities was assayed by proliferation assay, colony formation and flow cytometry analysis. The co-culture of TAM and human gastric cancer cell line MKN-45 were performed to understand whether the VIP affects the gastric cancer cells via TAM. Further, the tumor formation in a nude mouse model and VIP injection were performed to illustrate the effect on tumor progression in vivo. CD68 was high expressed in gastric cancer indicating high level of TAM in gastric cancer. Treatment with VIP significantly depressed TAM activation. Moreover, the expression of TNFα, IL-6, IL-12 and iNOS in TAM were depressed by VIP treatment, and the VIP treated TAM depressed gastric cancer cells. The experiment in the nude mouse model also suggested that by injection with TAM+VIP, the tumor volume and tumor weight were both decreased significantly. These data suggest that treatment with VIP inhibits gastric cancer.

View Figures

View References

1	Roder DM: The epidemiology of gastric cancer. Gastric Cancer. 5(Suppl 1): S5–S11. 2002. View Article : Google Scholar
2	Cervantes A, Roda D, Tarazona N, Roselló S and Pérez-Fidalgo JA: Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev. 39:60–67. 2013. View Article : Google Scholar
3	Mukhtar RA, Nseyo O, Campbell MJ and Esserman LJ: Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 11:91–100. 2011. View Article : Google Scholar
4	Noy R and Pollard JW: Tumor-associated macrophages: From mechanisms to therapy. Immunity. 41:49–61. 2014. View Article : Google Scholar : PubMed/NCBI
5	De Palma M and Lewis CE: Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 23:277–286. 2013. View Article : Google Scholar : PubMed/NCBI
6	Bingle L, Brown NJ and Lewis CE: The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol. 196:254–265. 2002. View Article : Google Scholar : PubMed/NCBI
7	Giraudo E, Inoue M and Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 114:623–633. 2004. View Article : Google Scholar : PubMed/NCBI
8	Delgado M and Ganea D: Vasoactive intestinal peptide: A neuropeptide with pleiotropic immune functions. Amino Acids. 45:25–39. 2013. View Article : Google Scholar
9	Vacas E, Bajo AM, Schally AV, Sánchez-Chapado M, Prieto JC and Carmena MJ: Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma. Mol Cell Endocrinol. 365:212–222. 2013. View Article : Google Scholar
10	Yang J, Shi QD, Song TB, Feng GF, Zang WJ, Zong CH and Chang L: Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro. Peptides. 42:105–111. 2013. View Article : Google Scholar : PubMed/NCBI
11	Delgado M and Ganea D: Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: Potential therapeutic role in brain trauma. FASEB J. 17:1922–1924. 2003.PubMed/NCBI
12	Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, Caro M, Orozco G, Gonzalez-Rey E and Martin J: Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: Altered expression and signal in immune cells. Arthritis Rheum. 58:1010–1019. 2008. View Article : Google Scholar : PubMed/NCBI
13	Delgado M and Ganea D: Cutting edge: Is vasoactive intestinal peptide a type 2 cytokine? J Immunol. 166:2907–2912. 2001. View Article : Google Scholar : PubMed/NCBI
14	Delgado M and Ganea D: Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. Arch Physiol Biochem. 109:377–382. 2001. View Article : Google Scholar
15	Gomariz RP, Arranz A, Abad C, Torroba M, Martinez C, Rosignoli F, Garcia-Gómez M, Leceta J and Juarranz Y: Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol. 78:491–502. 2005. View Article : Google Scholar : PubMed/NCBI
16	Arranz A, Juarranz Y, Leceta J, Gomariz RP and Martínez C: VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides. 29:948–956. 2008. View Article : Google Scholar : PubMed/NCBI
17	Laburthe M and Couvineau A: Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. Regul Pept. 108:165–173. 2002. View Article : Google Scholar : PubMed/NCBI
18	Brenneman DE: Neuroprotection: A comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Peptides. 28:1720–1726. 2007. View Article : Google Scholar : PubMed/NCBI
19	Voice JK, Dorsam G, Chan RC, Grinninger C, Kong Y and Goetzl EJ: Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul Pept. 109:199–208. 2002. View Article : Google Scholar : PubMed/NCBI
20	Collado B, Carmena MJ, Clemente C, Prieto JC and Bajo AM: Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model. Peptides. 28:1896–1901. 2007. View Article : Google Scholar : PubMed/NCBI
21	Balkwill F: TNF-α in promotion and progression of cancer. Cancer Metastasis Rev. 25:409–416. 2006. View Article : Google Scholar : PubMed/NCBI
22	Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS and Lam CW: Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol. 125:177–183. 2001. View Article : Google Scholar : PubMed/NCBI
23	Aktan F: iNOS-mediated nitric oxide production and its regulation. Life Sci. 75:639–653. 2004. View Article : Google Scholar : PubMed/NCBI
24	Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chiu HC, Dai YS, Inoue H, et al: Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 129:1016–1025. 2009. View Article : Google Scholar
25	Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng Q and Wang H, Chen J and Wang H: Tumor-associated macrophages recruit CCR6⁺ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One. 6:e194952011. View Article : Google Scholar
26	Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, Bidart JM, Chouaib S, Schlumberger M and Dupuy C: Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One. 6:e225672011. View Article : Google Scholar : PubMed/NCBI
27	Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH and Yang PC: Tumor-associated macrophages: The double-edged sword in cancer progression. J Clin Oncol. 23:953–964. 2005. View Article : Google Scholar
28	Martinez FO, Sica A, Mantovani A and Locati M: Macrophage activation and polarization. Front Biosci. 13:453–461. 2008. View Article : Google Scholar
29	Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
30	Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78. 2004. View Article : Google Scholar : PubMed/NCBI
31	Khorana AA, Ryan CK, Cox C, Eberly S and Sahasrabudhe DM: Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: A role for the host response in prognosis. Cancer. 97:960–968. 2003. View Article : Google Scholar : PubMed/NCBI
32	Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K and Lah TT: Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res. 29:3269–3279. 2009.PubMed/NCBI
33	Solinas G, Germano G, Mantovani A and Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 86:1065–1073. 2009. View Article : Google Scholar : PubMed/NCBI
34	Delgado M, Abad C, Martinez C, Leceta J and Gomariz RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med. 7:563–568. 2001. View Article : Google Scholar : PubMed/NCBI
35	Delgado M and Ganea D: Inhibition of IFN-γ-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol. 165:3051–3057. 2000. View Article : Google Scholar : PubMed/NCBI
36	Ganea D and Delgado M: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med. 13:229–237. 2002. View Article : Google Scholar : PubMed/NCBI
37	van Horssen R, Ten Hagen TL and Eggermont AM: TNF-α in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist. 11:397–408. 2006. View Article : Google Scholar : PubMed/NCBI
38	Krejs GJ: VIPoma syndrome. Am J Med. 82B:37–48. 1987. View Article : Google Scholar